Clinical data | |
---|---|
Other names | 5-spiro-(2'-ethyl-3'-5'-dimethyl-cyclopentyl)barbituric acid |
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number |
|
UNII |
|
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C12H18N2O3 |
Molar mass | 238.287 g·mol |
3D model (JSmol) | |
SMILES
| |
(verify) |
Spirobarbital is a barbiturate derivative developed by Eli Lilly in the 1940s. It has hypnotic and sedative effects, and has a moderate potential for abuse.
References
- US 2561688, Doran WJ, Van Heyningen EM, "Spirobarbituric Acids", issued 24 July 1951, assigned to Eli Lilly and Company
- Isbell H, Chruściel TL (1970). "Dependence liability of "non-narcotic" drugs". Bulletin of the World Health Organization. 43 (Supplement): 5–104. PMID 20718122.
GABAA receptor positive modulators | |
---|---|
Alcohols | |
Barbiturates |
|
Benzodiazepines |
|
Carbamates | |
Flavonoids |
|
Imidazoles | |
Kava constituents | |
Monoureides | |
Neuroactive steroids |
|
Nonbenzodiazepines | |
Phenols | |
Piperidinediones | |
Pyrazolopyridines | |
Quinazolinones | |
Volatiles/gases |
|
Others/unsorted |
|
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators |
This sedative-related article is a stub. You can help Misplaced Pages by expanding it. |